Meghan Gutierrez, Chief Executive Officer of the Lymphoma Research Foundation, explains the typical diagnostic journey for lymphoma patients, particularly those with follicular lymphoma.
As described by the NIH, follicular lymphoma is the second most common non-Hodgkin lymphoma accounting for approximately 15% of all lymphomas in North America.
Presentation of follicular lymphoma includes asymptomatic peripheral adenopathy in cervical, axillary, inguinal and femoral regions of the lymph nodes and usually waxing and waning of the lymph nodes as well.
Fortunately, follicular lymphoma is a slow-growing cancer and treatment options are available. Treatment for symptomatic follicular lymphoma is often chemotherapy or radiation therapy while asymptomatic patients may simply be watched. Recently, the FDA granted accelerated approval to tazemetostat for adults with refractory or relapsed follicular lymphoma.
To learn more about follicular lymphoma and other rare cancers, visit checkrare.com/diseases/cancers/